Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.
Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM; International Immuno-Oncology Biomarker Working Group.
Hudeček J, et al. Among authors: rimm dl.
NPJ Breast Cancer. 2020 May 12;6:15. doi: 10.1038/s41523-020-0155-1. eCollection 2020.
NPJ Breast Cancer. 2020.
PMID: 32436923
Free PMC article.
Review.